Floatz logo

Elbasvir

Metabolic Syndrome

Institute Of Cardiology & Internal Diseases, KazakhstanSmall moleculePhase 3Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

44 Active assets in the Metabolic Syndrome cohort.

View all 50

Same molecule, other indications

Elbasvir is also rated in:

hepatitis C virus infectionDormant
BBB
Indicative ·
75 / 100
View asset →
chronic hepatitis C virus infectionDormant
BBB
Indicative ·
72 / 100
View asset →
cirrhosis of liverDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →